BioMarin Pharmaceutical Inc. - Common Stock (BMRN)

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

BioMarin Pharmaceutical currently trades at $55.56 per share and has shown little upside over the past six months, posting a small loss of 4.4%. The stock also fell short of the S&P 500’s 11.5% gain during that period.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin Pharmaceutical (NASDAQ:BMRN).

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

Shares in the biotech company have surged on news of a big pharma takeover.

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the nascent power of quantum computing and the burgeoning might of renewable energy, these innovations are not merely incremental improvements; they are

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. 

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

BioMarin presents a strong value investment case with low valuation multiples, robust profitability, and a healthy balance sheet, all while showing solid growth potential.

BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander Hardy credited global demand for therapies like VOXZOGO and PALYNZIQ, noting, “These strong results are driven by the performance of our global enzyme therapies and Skeletal Conditions business units as we deliver for patients around the world.” The company’s operating margins declined due to higher R&D and SG&A expenses, partly from the Inozyme Pharma acquisition. Management acknowledged that this charge, along with business unit investments, weighed on profitability.

Although the company recorded higher sales overall, it's decided to divest one of its products.

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a slight increase in its full-year revenue forecast. 

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.18 billion at the midpoint. Its non-GAAP profit of $0.12 per share was 62.5% below analysts’ consensus estimates.

BioMarin (BMRN) Q3 2025 Earnings Call Transcript

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.18 billion at the midpoint. Its non-GAAP profit of $0.12 per share was 62.5% below analysts’ consensus estimates.

BioMarin's Q3 2025 results show mixed performance with revenue growth but a significant earnings miss, while the company raises its full-year outlook.

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know.